中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2015年
19期
30-31
,共2页
慢性阻塞性肺疾病%噻托溴铵%疗效
慢性阻塞性肺疾病%噻託溴銨%療效
만성조새성폐질병%새탁추안%료효
Chronic obstructive pulmonary disease%Tiotropium%Efficacy
目的：评价噻托溴铵对稳定期中重度慢性阻塞性肺疾病(COPD)的疗效。方法：收治稳定期 COPD 患者60例，随机分成试验组和对照组，试验组在常规治疗的基础上吸入噻托溴铵，对照组仅行常规治疗，观察时间12周，分别进行COPD评分(CAT)、圣乔治生活质量问卷(SGRQ)、肺功能检查如1秒钟用力呼气量(FEV1)和1秒钟用力呼气量占用力肺活量的百分比(FEV1/FVC)等，记录患者的不良反应。结果：用噻托溴铵干预后，试验组CAT及SGRQ评分分别下降(6.9±0.5)和(12.6±0.7)，与对照组比较差异有统计学意义(P＜0.05)。吸入噻托溴铵后，试验组 FEV1、FEV1%、FEV1/FVC等肺功能指标明显改善，与对照组比较差异有统计学意义(P＜0.05)。与噻托溴铵相关的不良反应主要有口干，发生率10%。结论：使用噻托溴铵可以显著减轻稳定期COPD患者的临床症状，改善患者的肺功能，提高患者的生活质量。
目的：評價噻託溴銨對穩定期中重度慢性阻塞性肺疾病(COPD)的療效。方法：收治穩定期 COPD 患者60例，隨機分成試驗組和對照組，試驗組在常規治療的基礎上吸入噻託溴銨，對照組僅行常規治療，觀察時間12週，分彆進行COPD評分(CAT)、聖喬治生活質量問捲(SGRQ)、肺功能檢查如1秒鐘用力呼氣量(FEV1)和1秒鐘用力呼氣量佔用力肺活量的百分比(FEV1/FVC)等，記錄患者的不良反應。結果：用噻託溴銨榦預後，試驗組CAT及SGRQ評分分彆下降(6.9±0.5)和(12.6±0.7)，與對照組比較差異有統計學意義(P＜0.05)。吸入噻託溴銨後，試驗組 FEV1、FEV1%、FEV1/FVC等肺功能指標明顯改善，與對照組比較差異有統計學意義(P＜0.05)。與噻託溴銨相關的不良反應主要有口榦，髮生率10%。結論：使用噻託溴銨可以顯著減輕穩定期COPD患者的臨床癥狀，改善患者的肺功能，提高患者的生活質量。
목적：평개새탁추안대은정기중중도만성조새성폐질병(COPD)적료효。방법：수치은정기 COPD 환자60례，수궤분성시험조화대조조，시험조재상규치료적기출상흡입새탁추안，대조조부행상규치료，관찰시간12주，분별진행COPD평분(CAT)、골교치생활질량문권(SGRQ)、폐공능검사여1초종용력호기량(FEV1)화1초종용력호기량점용력폐활량적백분비(FEV1/FVC)등，기록환자적불량반응。결과：용새탁추안간예후，시험조CAT급SGRQ평분분별하강(6.9±0.5)화(12.6±0.7)，여대조조비교차이유통계학의의(P＜0.05)。흡입새탁추안후，시험조 FEV1、FEV1%、FEV1/FVC등폐공능지표명현개선，여대조조비교차이유통계학의의(P＜0.05)。여새탁추안상관적불량반응주요유구간，발생솔10%。결론：사용새탁추안가이현저감경은정기COPD환자적림상증상，개선환자적폐공능，제고환자적생활질량。
Objective:To discuss the clinical effect observation of tiotropium for moderate to severe chronic obstructive pulmonary disease.Methods:60 patients with stable COPD were selected.They were randomly divided into the experimental group and the control group.The experimental group based on the conventional treatment using inhalation of tiotropium bromide.The control group only received routine treatment.The observation time of 12 weeks,respectively by COPD score(CAT),St.George's quality of life questionnaire(SGRQ),pulmonary function tests such as 1 second forced expiratory volume(FEV1)and 1 second forced expiratory volume percentage of hard vital capacity (FEV1/FVC),recording the adverse reactions of patients.Results:After tiotropium intervention,the experimental group CAT and SGRQ score were respectively decreased (6.9±0.5) and (12.6±0.7),and there was statistically significant(P<0.05).After inhaling tiotropium,the experimental group of FEV1,FEV1%,FEV1/FVC and other lung function parameters were significantly improved,and there was statistically significant(P<0.05).With tiotropium bromide related adverse reactions were mainly dry mouth,and the incidence was 10% .Conclusion:The use of tiotropium bromide can significantly relieve the clinical symptoms of COPD patients on stable stage,improve pulmonary function of patients,and improve the patient's quality of life.
